laurahong – Accestra Consulting https://www.accestra.com Your long term strategic partner for regulatory compliance. Tue, 08 Jun 2021 04:05:16 +0000 en-US hourly 1 https://wordpress.org/?v=6.5.5 https://www.accestra.com/wp-content/uploads/2019/03/cropped-accestra2-32x32.png laurahong – Accestra Consulting https://www.accestra.com 32 32 Time for Cruelty-free/Non-Animal Testing in China https://www.accestra.com/time-for-cruelty-free-non-animal-testing-in-china/ Thu, 03 Jun 2021 08:29:45 +0000 http://www.accestra.com/?p=3928
Animal testing is conducted on animals such as rabbits (usually in Chinese labs) and guinea pigs.
 
This is toxicological testing for reactions such as eye irritation or skin irritation,
 
A majority of overseas brands from Europe, America, Australia, and New Zealand are cruelty-free and don’t do animal testing. But China, as a huge emerging market, comprises of up to 80% of market shares for overseas brands.
 
This is quite a dilemma for “cruelty-free” brands that rely on the Chinese market.

Changes to animal testing in China

The release of CSAR 2020 in June 2020 signified to the world that China had finally taken a “no animal testing” approach.

However, not all cosmetics can be exempted from animal testing.

Apply for a safety assessment report instead of animal testing

There is a premise for exemption from animal testing where you can apply for a safety assessment report instead:
  • General cosmetics ONLY (not applicable to special cosmetics).
  • The results of the safety risk assessment report can completely verify the product’s safety.
  • The manufacturer has obtained relevant certification (such as GMP) of the production quality management system issued by the competent governmental authorities of the original country (region), not by any third parties/organizations like SGS.
*Note: If there is more than one actual manufacturer (such as OEM/ODM), everyone must get the required certification.

Situations where animal testing in China must be conducted

The below situations CANNOT be exempted from animal testing:
  • Children or baby products (children under 12 years old).
  • Using new cosmetic ingredients in formulation (those not included in IECIC 2021).
  • Brand owner (foreign applicant company), responsible person (domestic RP company), or manufacturer (if any OEM/ODM) are on key-supervision blacklist according to NMPA supervision ranking.

Changes for animal testing in China from 2022

From 1 January 2022 a safety assessment report will be mandatory for new applications with or without doing animal testing

For more information and support with this process, please contact Accestra Consulting Group.

Contact Accestra Consulting Group
]]> Natural Health Products NZ – 2021 China Market Update https://www.accestra.com/natural-health-products-nz-2021-china-market-update/ Fri, 30 Apr 2021 10:41:17 +0000 http://www.accestra.com/?p=3704
  • Date: Tuesday, 9th March, 2021
  • Time: 7:30 AM – 8:30 AM CST (China Standard Time)
  • Price: Free of charge

Click here to register. You will then receive an invitation to this webinar. Please note that the number of participants is limited.

TOPICS and SPEAKERS:

  • Pete Frost: Trade Commissioner, Greater China, New Zealand Trade & Enterprise (NZTE)
  1. Welcome & Introduction
  • Zhang Zhongpeng: Director of CCCMHPIE, China Chamber of Commerce for Import & Export of Medicines & Health Products (CCCMHPIE)

2.1 China Nutrition & Health Care: An Overview

2.2 Latest policy and the impact for overseas companies; 2020 sector data

3.1 Market Access & Regulation by Sector

3.2 A closer look at the regulatory framework; market access tips & techniques for

      brand owners and ingredients suppliers

  • Monika Xing, Deputy Director of Health & Nutrition Department, China Chamber of Commerce for Import & Export of Medicines & Health Products (CCCMHPIE)

4.1 New Sales & Marketing Opportunities in China

4.2 Trends and shifts in consumer perceptions, behaviour, sales channels and social

      media

Accestra Consulting provides China regulatory affairs outsourcing for Drugs/Pharmaceutical, Food and feed products for China NMPA (formerly CFDA) regulatory approval including product registration for China, China Drug Master File (DMF) for APIs, Excipient and Packaging Materials and others. For more information you may email info@accestra.com.

]]> China Path Podcast https://www.accestra.com/china-path-podcast/ Tue, 12 May 2020 02:35:57 +0000 http://www.accestra.com/?p=3746

Due to the US-China trade war, American delegates at Shanghai’s SIAL Food Expo decreased by 50% this year. No wonder China’s market has become more difficult for US firms when, for example, US wine tariffs are 70% (no FTA and trade war tariffs) while Australia’s are 0% (ChAFTA).

On the latest Australia China Business Council podcast, James Scullin speaks with Raymond Ng from Accestra Consulting on the trade war’s effect on business and the most common reasons why goods get rejected at customs, such as labeling, ingredients and non-compliance testing. We discuss China’s new draft legislation on animal testing requirements, how individual ports function uniquely and how to avoid trademark squatters.

Click here to register. You will then receive an invitation to this webinar. Please note that the number of participants is limited.

]]> NZTE CHINA DIGITAL SPEAKER WEBINAR SERIES https://www.accestra.com/nzte-china-digital-speaker-webinar-series/ Sun, 10 May 2020 10:22:55 +0000 http://www.accestra.com/?p=3719
  • Date: Tuesday, 12th May, 2020
  • Time: 13:30-14:30 CST (China Standard Time)
  • Price: Free of charge

Brought to you by New Zealand Trade and Enterprise (NZTE), this webinar series has been designed to help your business navigate the shifting digital landscape in post-COVID China. From mastering your digital strategy and optimising your social media investment, to understanding consumer behaviour and regulatory considerations/compliance, our experts will equip you with the insights and tools you need to adapt and grow your business in this recovering market.

Click here to register. You will then receive an invitation to this webinar. Please note that the number of participants is limited.

TOPICS and SPEAKERS:

  • Sheng Pang, Beachhead Advisor, NZTE and CEO, Juplus
  1. China digital marketing insights for Covid-19 recovery and best predictions for 2021

 

  • Mark Tanner, Managing Director, CHINA Skinny
  1. Consumer behavioural changes resulting from COVID-19

 

  • Coolio Yang, Founder, Coolio Yang Consultant
  1. Optimising return on your social media investment

 

  • Raymond Ng, Senior Regulatory Manager, Accestra

Ricky Yang, Managing Director, KJ Bass

  1. China compliance and market access in the digital world

 

  • Louie Li, Beachhead Advisor, NZTE and Manager Director, Ctom Group

Vivian Sun, Founder and CEO, BestL2

Carter Yan, General Manager, New Zealand Healthcare Group

  1. How to grow your revenue through the changing daigou business models: ‘Daigou 2.0’

Accestra Consulting provides China regulatory affairs outsourcing for Drugs/Pharmaceutical, Food and feed products for China NMPA (formerly CFDA) regulatory approval including product registration for China, China Drug Master File (DMF) for APIs, Excipient and Packaging Materials and others. For more information you may email info@accestra.com.

]]>